This month, in celebration of International Women’s Day, MMV women in R&D discuss childhood heroines, progress that has been made for women in science over the course of their careers and inspiring young women to follow a science path.

DSM265 is one of the new generation of novel antimalarials and has the potential to both treat patients and protect healthy people with a reduced dosing schedule. Dr Jörg Möhrle talks about the potential of DSM265 and its role in validating the sporozoite volunteer infection study platform.

MMV and partners have developed and implemented a series of platforms to gather data to feed into a tool that enables everycompound pair to be compared in a similar manner. This allows unbiased prioritization of optimal drug combinations for further research. Dr Nicole Andenmatten explains how new tools are being employed to determine which drug combinations should progress further.

MMV048 is a novel antimalarial compound from the aminopyridine class, with important activity across the entire parasite lifecycle. Dr Cristina Donini explains her vision for MMV048, as well as the importance of getting the formulation right and building clinical trial capacity in Ethiopia.

Tafenoquine is an investigational medicine in phase III development. If approved, it would be the first new medicine to cure relapsing malaria in over 60 years. Dr Wiweka Kaszubska and Dr JP Kleim provide an update on the phase III programme.

The GSK692 project team was awarded MMV's 2015 Project of the Year. Dr Paul Willis and Dr Laura Sanz talk about the award, the compound, and the collaboration.

Alexis works with teams in the six countries providing technical and analytical support to implement the UNITAID-funded ISMO project. As the project nears the end of its 3-year grant, Alexis talks about his experiences and what has been learnt.

David Reddy speaks with Marcus Papadopoulos of Politics First magazine, about the successes scored against malaria and the new challenges emerging in this fight. 

At this year’s ASTMH Annual Meeting, tweets are taking the place of microscopes as we hear from meeting participants. More #IamTropMed photos and stories are being shared via Twitter 2-6 November 2014.

David Reddy speaks with International Innovation and lays out MMV's ambitious short-term goals, and outlines the projects that are bringing new antimalarial drugs to those most in need. 

DDD498 has potent activity against multiple stages of the malaria parasite’s lifecycle, giving it the potential to cure and stop the spread of the disease as well as protect people, all in a single-exposure. Dr Paul Willis and Dr Lidiya Bebrevska discuss recent progress and next steps. 

MMV has become part of the ACCESS-SMC consortium, which is supporting the implementation and scale-up of SMC in the Sahel region. Adam Aspinall, Director, Product Strategy & Management explains the role of MMV and the implementing partners. 

The Malaria Box was launched in response to the need for access to physical samples of molecules to initiate drug discovery programmes for malaria and neglected diseases. The Pathogen Box is modelled on the success of the Malaria Box. Dr Thomas Spangenberg tells us how the Malaria Box is being used today and what's in store for the Pathogen Box. 

MMV and partners are working to identify and develop molecules that are fast acting and have a long duration of action for combination into a single-dose cure and first-generation SERCaP. Dr Marc Adamy explains the strategy to accelerate the development of OZ439. (2013)

Tafenoquine entered Phase III in April 2014, taking it closer to becoming the only new medicine approved for the treatment of relapsing malaria in over 60 years. Dr Jörg Möhrle & Dr Wiweka Kaszubska talk about the challenges, the partnership and what the future holds. 

Experts from DNDi, MMV and TB Alliance speak about progress in R&D

This series on international cooperation by Radio Télévision Suisse features three MMV staff.

A novel antimalarial compound from the aminopyridine class, MMV390048, was awarded MMV's Project of the Year. Dr Cristina Donini took over as Project Director in July 2012, when the compound was selected as a candidate. She tells us what's next for this compound.

Mark Baker, a clinical pharmacologist, explains two innovations that are enabling MMV to accelerate the collection and use of PK/PD data to speed the development of next-generation antimalarials. 

Dr Tim Wells speaks about MMV at The World Conference of Science Journalists, the Middle East and malaria.

Monitoring post-approval drug safety has become a matter of increasing importance, as it enables us to maximize the safe use of registered medicines. Dr Stephan Duparc explains what pharmacovigilance means for MMV. 

MMV recently signed a historic agreement with the African Leaders Malaria Alliance, an alliance of African Heads of State seeking to work together to combat malaria in Africa.

OZ439 is a fully synthetic peroxide on track to provide not only a single-dose cure for malaria, but also a potential alternative to currently used artemisinin derivatives. Dr Jörg Möhrle explains this molecule.